ALD Connect, an all-inclusive consortium to eradicate adrenoleukodystrophy
|
|
- Ashlynn Clara Bruce
- 6 years ago
- Views:
Transcription
1 ALD Connect, an all-inclusive consortium to eradicate adrenoleukodystrophy Breakfast Seminar 4: Patient Powered Research Networks for Rare Diseases October 10 th, 2015 Florian Eichler, MD Center for Rare Neurological Diseases Massachusetts General Hospital
2 Financial Disclosures PI of ex vivo len,viral gene therapy trial in adrenoleukodystrophy sponsored by bluebird bio PI of L- serine trial in HSAN1 sponsored by FDA Orphan Disease Group Consultant to Retrophin on Cerebrotendinous Xanthomatosis Consultant to Alexion Pharmaceu,cals on MOCD Consultant to Third Rock Ventures on rare neurological disorders
3 History of Adrenoleukodystrophy not unlike that of other rare neurological disorders Haberfeld and Spieler in 1910: Exercise for AMN in 2015: Drama film in 1992:
4 The world is changing Serbian border Human beings are more willing to endure risk and suffering for the chance of a benefit Island of Lesbos
5 The world is also changing for rare diseases Flicker of Hope for Children With Rare and Devasta,ng Disease (RCDP), New York Times, September 2015 The Wall Street Journal Reports On FDA Approval of Cyclodextrin Treatment for Niemann Pick Type C, April 2009
6 The world is also changing for rare diseases Increased Detection of Mendelian Traits (AM Glazier et al, Science 2002). Increase in orphan drug designations (Melnikova, Nature Reviews Drug Discovery 2012)
7 ALD Connect The mission of the is to improve medical care and health outcomes for with adrenoleukodystrophy, through advancing knowledge, raising awareness, and improving Our vision: to the prac9ce of medicine by iden9fying, op9mizing, and implemen9ng advances in the care and cure of adrenoleukodystrophy in a mul9center network. Our goal is to achieve complete disease eradica9on through coopera@on between pa9ents, pa9ent- advocate groups, clinicians, researchers, industry, and government.
8 Annual Boston 2013 Annual 2014
9 Much to Celebrate! September 25 th, 2015 August 27 th, 2015: Federal advisory commitee for diseases in newborns voted to recommend the of ALD to the newborn screening list
10 But also much work ahead - Approx AMN pa9ents, men and women, in U.S. currently have no treatments - This year 40 boys in U.S. will undergo bone marrow transplanta9on. A third will be too advanced for op9mal transplant. - This year another 20 boys in U.S. will not even have any treatment op9ons due to severity of cerebral ALD
11 misdiagnosis persists in ALD families
12 How does ALD Connect work together? Board of Directors Work Group 1: Infrastructure, Governance and Funding Work Group 2: Outcome Measures Work Group 3: Disease mechanisms Work Group 4: Dissemina9on of ALD- related Disease Informa9on Biomarkers Summit Organizing CommiTee Drug Algorithm Website Development Physician Awareness Engagement Doctor Webinars
13 How to make progress together? Board of Directors Engage in collaborative discussions Mindful of the mission of the consortium Strive for consensus, not simply rule by majority Have all voices heard, respectful of all All inclusive!
14 Academic Collaborate Members and Affiliate Members
15 NeuroBANK physician portal Current'Number'of'pa/ents'enrolled'for' ALD'Natural'History ' Total'number'of'pa/ents'''''''''''''82' Number'of'adults'(18+)''''''''''''''''50' Number'of'children'(<18)''''''''''''26' No'demographics'data''''''''''''''''''6'
16 PATIENT PORTAL hsps://nctu.partners.org/ald/ Number'of'pa,ents:'190' Number'of'adults:'111' Number'of'children:'29' Did'not'provide'age:'50'
17 Center for Rare Neurological Diseases (CDRN) MISSION: To eradicate rare disorders of the nervous system by leveraging the power of biological insights towards design and implementation of clinical trials Building on synergies with the CHGR, the center will establish partnerships that advance treatments for rare diseases. It will do this by recognizing and harnessing unmet needs and biological insights of rare diseases providing resources to enable investigators fill knowledge gaps and move from bench to bedside creating partnerships and collaborations across patient communities, academia and industry
18 Center for Rare Neurological Diseases (CDRN) MGH, MEEI and Boston Children s Hospital 8 departments and 8 companies represented MGH Rare Disease Think Tank: Strategic Discussions Across Departments and Industry
19 MGH Rare Disease Think Tank Endocrinology Psychiatry Children s Hospital CHGR Neurology CHGR Mass Eye&Ear Pfizer Cydan Third Rock Pulmonology Sanofi-Genzyme Nephrology Neurology Genetics Agilis Partners Innovation Retrophin Oncology Synageva Strategic Discussions Across Departments, Hospitals and Industry
20 CDRN: Working together on Rare Neurological Diseases Projects to Accelerate Research for Neurological Indications
21 Example: Ex Vivo Lentiviral Gene Delivery in Boys with Cerebral Adrenoleukodystrophy boys dying from neurogenetic disorder Haberfeld and Spieler, 1910 Patient Centered Outcomes Research Institute (PCORI) award for ALD Connect Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of CCALD Collaboration: Boston Children s (Drs. Williams & Duncan), MGH (Dr. Eichler) Sponsor: bluebird bio Cartier, Aubourg, 2009 Hematopoetic stem cell correction halts the progression of devastating inflammatory demyelination in the brain, prompting first gene therapy trial, now ALD added to RUSP.
22 With Emerging Therapies Patients Emerge
23 Early detection and targeted therapies can be transformative
24 Steps in Therapy Development for Single Gene Disorders 1. Biological Insights Function of Disease Causing Genes 2. Emerging Therapeutic Identified Ability to correct dysfunction (POC) Reaches CNS 3. Understanding of Disease Course natural history studies outcome measures Clinical Trial Design becomes possible
25 Trial Design requires Natural History n Placebo arm for rare devasta9ng diseases ozen not acceptable n Therapeu9c window needs to be clear
26 Emerging Therapies in Mendelian Disorders (POC studies entering clinical arena) n n n n n n n ERT Trials Ex Vivo Gene Therapy In Vivo Gene Therapy Cell-based Therapy Immunomodulatory Therapy ASO Therapy Gene Editing Key Question: Are Disorders Gain of Function or Loss of Function?
27 CDRN: Identifying Opportunities and Knowledge Gaps
28 Strategic Partnerships for Accelerated Progress in Rare Neurological Diseases Understanding common challenges can bring multiple stakeholders together Unmet needs and desperate diseases can break down traditional boundaries Partnerships across disciplines and institutions possible Industry, patient advocacy and academia can complement each other Patient engagement and perspective can provide focus: Move from Engagement Readiness to Trial Readiness!
Press Release. Interim Data Summary
Print Page Close Window Press Release bluebird bio Reports Interim Clinical Data from Starbeam Study of Lenti-D at AAN 2016 Annual Meeting First clinical data to be presented from Phase 2/3 Starbeam Study;
The Cell and Gene Therapy Catapult UK clinical trials database
The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)
Orchard Therapeutics. Overcoming the complex challenges associated with ex vivo gene therapies. Adrien Lemoine VP Business Development & Operations
Orchard Therapeutics Overcoming the complex challenges associated with ex vivo gene therapies Adrien Lemoine VP Business Development & Operations Orchard at a glance Who we are Our mission Team Academic
Stem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
The Cell and Gene Therapy Catapult UK clinical trials database
The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Michael Werner Executive Director Alliance for Regenerative Medicine ARM s Focus & Role As the leading global advocate for the regenerative medicine and advanced therapies
Employment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
HEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE
HEALTH POLICY AND DRUG PRICING: A RESEARCHER S PERSPECTIVE NATASHA KEKRE, MD, MPH, FRCPC NOV 16, 2016 www.ohri.ca WHY THIS MATTERS TO ME I am a hematologist in Ottawa with 75% dedicated time for research
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What
The Curative and Transformative Potential of Novel Therapies for Rare Diseases in the Age of Precision Medicine
The Curative and Transformative Potential of Novel Therapies for Rare Diseases in the Age of Precision Medicine Christopher P. Austin, M.D. Director, NCATS/NIH EveryLife Scientific Workshop September 12,
NETWORKING AND CUREACCELERATOR LIVE!
RARE DRUG DEVELOPMENT SYMPOSIUM A PARTNERSHIP BETWEEN PENN MEDICINE ORPHAN DISEASE CENTER AND GLOBAL GENES PHILADELPHIA, PENNSYLVANIA NETWORKING AND CUREACCELERATOR LIVE! CureAccelerator Live! Rare Disease
Docket #: FDA-2018-D-3268
Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international
Cell and Gene Therapy Catapult clinical trials database
Cell and Gene Therapy Catapult clinical trials database Executive summary The number of cell and gene therapy clinical trials in the UK continues to increase with 85 ongoing trials at present, representing
Creation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),
Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,
From regulation to reality challenges in translation of gene therapy and cell-based medicinal products
From regulation to reality challenges in translation of gene therapy and cell-based medicinal products Gene therapy case study: ADA-SCID Alessandro Aiuti Jonathan Appleby HSR-TIGET is focused on the implementation
Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018
Medical Topics: Gene Therapy E. Anne Jackson, FSA MAAA July 30, 2018 Agenda Terminology Crash course in the science Existing FDA-approved gene therapies Underwriting implications 2 Terms related to high
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
December 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
December 4, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2014 N 1698: Food and Drug Administration Activities
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
Statistical Challenges: Designs for clinical trials with limited patient populations
Statistical Challenges Statistical Challenges: Designs for clinical trials with limited patient populations Simon Day, PhD simon.day@ctct-ltd.co.uk 1 Conflicts of interest (sorry!) 2 What do statisticians
Expert Conference on Revision of Declara?on of Helsinki Tokyo, Japan. On March 1, 2013 Professor Somkiat Wa/anasirichaigoon, MD, FRCST
Expert Conference on Revision of Declara?on of Helsinki Tokyo, Japan. On March 1, 2013 Professor Somkiat Wa/anasirichaigoon, MD, FRCST Chairman, Medical Educa?on Sec?on, Medical Associa?on of Thailand
Stem Cell Uses and FDA Regulation
Stem cells have been called everything from cure-alls to miracle treatments. But don t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware
On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic
Robert J. Beall, Ph.D. President and Chief Executive Officer Cystic Fibrosis Foundation On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic fibrosis (CF) in the United States,
REIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS
ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS 2018-2024 ORACLE 2.0: Leading Globally, from Innovation to Impact P1 P2 NOTE FROM OUR LEADERS NOTE FROM VP RESEARCH,
Pediatric Cancer Drug Development: Impact of US Regulations
Pediatric Cancer Drug Development: Impact of US Regulations Martha Donoghue, M.D. Acting Associate Director, Division of Oncology Products 2 Office of Hematology and Oncology Products Center for Drug Evaluation
Regulatory Pathways for Rare Diseases
Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box. The purpose of this presentation Looking for Joint Venture
Precision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease
Precision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease Session #61, February 20, 2017 Jason Levine, MD, Assoc. Director of Clinical Informatics,
The Construction of a Clinical Trial. Lee Ann Lawson MS ARNP CCRC
The Construction of a Clinical Trial Lee Ann Lawson MS ARNP CCRC 1 Objectives Review Phases of Clinical Research Discuss Orphan Drug Act Discuss regulatory agencies Overview phases of clinical research
New Drug Application (NDA) Webinar December 6, 2016
New Drug Application (NDA) Webinar December 6, 2016 Introduction Presenter: Jill Jarecki Chief Scientific Officer, Cure SMA New Drug Application Process NDA Not yet an approved therapy: ~90% chance of
Stem Cells Regenerative Medicine Congress September 15, 2014
Stem Cells Regenerative Medicine Congress 2014 September 15, 2014 Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use
March 2, Dear Chairman Upton, Ranking Member Pallone, and Representative DeGette:
March 2, 2015 The Honorable Fred Upton Chairman Energy and Commerce Committee House of Representatives Washington, DC 20515 The Honorable Frank Pallone Ranking Member Energy and Commerce Committee House
Defining the Expertise for the 21 st Century Neuroscience Workforce. James E. Barrett, Ph.D. Professor and Chair
Defining the Expertise for the 21 st Century Neuroscience Workforce James E. Barrett, Ph.D. Professor and Chair Department of Pharmacology and Physiology Drug Discovery and Development Program at Drexel
A gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao. REPROCELL Inc., 2017
Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao 1 29 th November, 2017 Collaboration with Q therapeutics to develop new ipsc therapies for CNS diseases REPROCELL announced a
Molecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
Post-doctoral PharmD Fellowship Programs
Post-doctoral PharmD Fellowship Programs Table of Contents About Bioverativ Messages from Medical & Regulatory Our Pipeline Partnership with Northeastern University Global Medical Fellowship Global Regulatory
Gene therapy. Findings by Alert
Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
Voyager Therapeutics - A Spinout from UMass Gene Therapy and RNAi Technologies
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2016 UMass Center for Clinical and Translational Science Research Retreat
The Leader in AAV Gene Therapy. A Guide to AAV Gene Therapy for MPS I and II
The Leader in AAV Gene Therapy A Guide to AAV Gene Therapy for MPS I and II REGENXBIO seeks to understand the diverse perspectives of patients, caregivers and families, and to learn from their experiences
CPTR Mission, Structure & Goals for Innovation
CPTR Mission, Structure & Goals for Innovation Dr. Debra Hanna, PhD Executive Director Critical Path to TB Drug Regimens Event title - DD Month YYYY - Location The Challenge Collaborating for Cures 7 March
A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA
A GATEWAY TO ACADEMIC EXCELLENCE FOR BIOTECH AND PHARMA Découpe 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s Patient centered, translational technology
Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will
Bench Bedside Our job today Enlist you to help us cross the Translational Divide between the lab bench and the patient s bedside Demonstrate that this will be done in our Kimmel Cancer Center at Hopkins,
A Patient/Advocate Perspective
ADAPTIVE DESIGNS IN CLINICAL DRUG DEVELOPMENT : Opportunities & Challenges A Patient/Advocate Perspective Jane Perlmutter janep@gemini-grp.com May 22, 2006 Topics Advocates Who are we? What do we do? Clinical
International Progressive Multiple Sclerosis Collaborative : Update on Research Strategy
International Progressive Multiple Sclerosis Collaborative : Update on Research Strategy Increasing disability Increasing disability Progressive Forms of MS Many MS patients begin with a relapsing form
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
Working Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017
Working Together for Better Health Partnering with Boehringer Ingelheim JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017 Welcome to Partnering with Boehringer Ingelheim Our guiding principle Value
FNIH: NASH Biomarker Consortium. Presenter: Roberto Calle on behalf of Foundation for the National Institutes of Health
FNIH: NASH Biomarker Consortium Presenter: Roberto Calle on behalf of Foundation for the National Institutes of Health LIVER FORUM Development of Non-invasive Biomarkers for Non-alcoholic Steatohepatitis
FACTS YOU NEED TO KNOW UNITED STATES OF AMERICA
CLINICAL TRIALS BROCHURE FACTS YOU NEED TO KNOW Thousands of men across the United States suffer from the difficult effects of prostate cancer and often undergo treatment that does not produce optimal
Rare Diseases and CDER: Challenges and Opportunities
Rare Diseases and CDER: Challenges and Opportunities The Science of Small Clinical Trials November 27 & 28, 2012 Kathryn O Connell, MD PhD Medical Officer, Rare Diseases Program Office of New Drugs, CDER,
IMI: Accelerated Drug Portal. Julia Brosnan on behalf of Innovative Medicines Initiative
IMI: Accelerated Drug Portal Julia Brosnan on behalf of Innovative Medicines Initiative Accelerating Medicines Partnership Type 2 Diabetes (AMP T2D) AMP T2D is a pre-competitive partnership among government,
May 9, Meeting Summary. Facilitating Antibacterial Drug Development
May 9, 2012 Meeting Summary Facilitating Antibacterial Drug Development Origins of the Current Public Health Crisis of Antibacterial Resistance Antibacterial drugs play a critical role in the ability to
Discovery of drugs and drug resistance. Model organisms. Plants and livestock. Cell-based disease modelling. Therapeutics
Genome editing for the engineering of cell lines and animal models Major applications are in: Discovery of drugs and drug resistance Model organisms Plants and livestock Cell-based disease modelling Therapeutics
Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013
Christopher P. Austin, M.D. Director, NCATS IOM CTSA Review Committee January 24, 2013 Basic Laboratory Research Clinical Research Improved Public Health Translational Research Population Research Basic
Bipartisan Policy Center, Top Medical Innovation Priorities
Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative
KPI Definition Comment Relates to Baseline Target
IMI2 Key performance indicators (KPIs) Reporting on measuring and outcomes on the ten following Key Performance Indicators will be provided yearly as part of the IMI2 JU Annual Activity Reports for year
Compassionate Use: Perspectives from a Patient Advocacy Group
Compassionate Use: Perspectives from a Patient Advocacy Group American Society of Clinical Oncology Annual Meeting 2016 Samantha Roberts, PhD Director of Scientific Affairs, Friends of Cancer Research
Food and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
Global Gene Therapy Market Report -2026
Global Gene Therapy Market Report -2026 July 2018 Table of Contents 1 Executive Summary 2 Gene Therapy: Overview Viral Vectors for Gene Therapy Viral Vectors Non-Viral Vectors Types of Gene Therapy Somatic
Patient Focused Drug Development 2.0
Patient Focused Drug Development 2.0 September 15, 2015 Pat Furlong, PPMD ParentProjectMD.org Understanding the Duchenne Muscular Dystrophy Environment 2 About Duchenne muscular dystrophy X-linked, pediatric
MMRF and MMRC. Collaborative Research Model for a Rare Disease. Susan L. Kelley, M.D. MMRF and MMRC 11/23/2009. Collaborative Model
Collaborative Research Model for a Rare Disease Susan L. Kelley, M.D. 1 OVERVIEW Multiple myeloma is an orphan blood cancer with a low 5-year survival rate. African American incidence is twice that of
Orphan Products and Drug Development 2015 MARLENE E. HAFFNER, MD MPH HAFFNER ASSOCIATES AS PRESENTED TO GLG SEPTEMBER 23RD, 2015
Orphan Products and Drug Development 2015 MARLENE E. HAFFNER, MD MPH HAFFNER ASSOCIATES AS PRESENTED TO GLG SEPTEMBER 23RD, 2015 What are Orphan's? Drug Development Rare Diseases Orphan Drug Act of 1983
Bone Marrow Failure Research Program
Bone Marrow Failure Research Program Strategic Plan INTRODUCTION The Congressionally Directed Medical Research Programs (CDMRP) represents a unique partnership among the U.S. Congress, the military, and
Rare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
Learning about Clinical Trials
Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the
While individually rare, orphan diseases are actually collectively common, with an OF ORPHAN DRUG DEVELOPMENT MEETING THE UNIQUE CHALLENGES
ELECTRONICALLY REPRINTED FROM JUNE 2017 CLINICAL TRIALS Rare Diseases: MEETING THE UNIQUE CHALLENGES OF ORPHAN DRUG DEVELOPMENT BY MICHAEL F. MURPHY, MD, Ph D While individually rare, orphan diseases are
Understanding the Gene Therapy Market Today
Understanding the Gene Therapy Market Today February 2017 Author: Richard Tinsley, Strategy Partner C International Contents A Case Study Utilizing Gene Therapy to Correct Genetic Vision Problem 1 Learning
TAK-CELERATOR. Introducing a new External R&D Initiative to Accelerate Development of Therapies in Rare Diseases. Patients Partnerships Performance
TAK-CELERATOR Introducing a new External R&D Initiative to Accelerate Development of Therapies in Rare Diseases Dr Christine Charman Findacure Scientific Conference The Royal College of Nursing, London
Orphan Medicinal Products
Development process of Orphan Medicinal Products 1 Did you know that... A rare disease is officially defined as a lifethreatening or chronically debilitating condition that affects no more than 5 in 10,000
Regulatory Market Update: What are the major changes and differences worldwide?
Regulatory Market Update: What are the major changes and differences worldwide? Marlene E. Haffner MD, MPH, CEO Haffner Associates Orphan Drug Summit 2015 Copenhagen, Denmark September 17, 2015 Orphan
COMMITMENT TO CITIZENSHIP
COMMITMENT TO CITIZENSHIP A Framework for Corporate Social Responsibility MEDICINES FOR PATIENTS EMPLOYEES ENVIRONMENT COMMUNITIES GOVERNANCE AND ETHICS AT MODERNA, OUR CORPORATE CITIZENSHIP IS BUILT UPON
Critical Path to TB Drug Regimens (CPTR)
Critical Path to TB Drug Regimens (CPTR) Why do we need a CPTR initiative? We finally have a pipeline of TB drug candidates Today, we test drugs same way we did 20 years ago Need better tests for drug
A unique Collaborative Model for the Discovery of New Therapeutic Approaches
A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA
National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
Pharma Outlook 2030: From evolution to revolution
Pharma Outlook 2030: From evolution to revolution The pharmaceutical sector at a crossroads considerations for your company s future operating model KPMG Global Healthcare & Life Sciences July 7, 2017
Update on Japan s Regulation of Cell-Based Therapeutic Products
NIHS Since 1874 Stem Cell & Regenerative Medicine Global Congress 2016 August 23, 2016 Gyeonggi-do, Korea Update on Japan s Regulation of Cell-Based Therapeutic Products Yoji Sato, Ph.D. Head, Division
2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award
2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award 2018 2018 NORTH AMERICAN REAL-WORLD EVIDENCE ENTERPRISE SOLUTIONS MARKET LEADERSHIP AWARD Contents Background and Company
CTTI Overview One Decade of Impact. One Vision Ahead.
Feb. 6, 2018 CTTI Overview One Decade of Impact. One Vision Ahead. Pamela Tenaerts, MD, MBA Executive Director #CelebrateCTTI Discover how CTTI has influenced the clinical trials enterprise during the
Dear NNPDF NPC Community, August 17 th, 2015
National Niemann-Pick Disease Foundation, Inc. 401 Madison Avenue, Suite B Post Office Box 49 Fort Atkinson, WI 53538-0049 Phone: 920-563-0930 Web: www.nnpdf.org Dear NNPDF NPC Community, August 17 th,
The Evolving Regulatory Landscape for Orphan Drugs: FDA Perspectives
The Evolving Regulatory Landscape for Orphan Drugs: FDA Perspectives Debra Lewis, O.D., M.B.A. Acting Director, Office of Orphan Products Development FDLI May 4, 2018 OOPD Core Programs Mission: To promote
Orphan Drug Topics: 1. Discovery of FDA s Flexibility 2. Evolving Voice of the Patient in Drug Review. February 21, 2018
Orphan Drug Topics: 1. Discovery of FDA s Flexibility 2. Evolving Voice of the Patient in Drug Review ISCTM 14 th Annual Scientific Meeting February 21, 2018 Frank Sasinowski, M.S., M.P.H., J.D fjs@hpm.com
Report from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
FRDA CLINICAL TRIALS. Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center. Meeting
FRDA CLINICAL TRIALS Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center US STUDIES FUNDED BY FARA, MDA, NAF, AND NIH FOR FA 18 16 14 12 10 8 6 4 2 0 1997 1998 1999 2000 2001 2002
Innovative Medicines Initiative
Innovative Medicines Initiative EMA - EBE Regulatory Conference on ATMPs Salah-Dine Chibout, Novartis Global Head Discovery & Investigative Safety/ Global Head Preclinical Safety Therapeutic Areas IMI
1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org July 7, 2009 Jerry Moore NIH Regulations Officer NIH, Office of Management Assessment 6011 Executive Boulevard, Suite
Gene Therapy for Fanconi Anaemia Hope or hype? Dr Phil Ancliff Great Ormond Street Hospital / UCL Institute of Child Health Twycross Zoo October 2017
Gene Therapy for Fanconi Anaemia Hope or hype? Dr Phil Ancliff Great Ormond Street Hospital / UCL Institute of Child Health Twycross Zoo October 2017 Gene therapy in Seattle Grace Miranda Bailey had the
Webinar IMI2 Call 13 Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
Webinar IMI2 Call 13 Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative 27.11.2017 15:00 CET Agenda How to use GoToWebinar Catherine Brett,
EXPERT CONFERENCE ON THE REVISION OF DECLARATION OF HELSINKI IMPERIAL HOTEL, TOKYO TOKYO, JAPAN FEBRUARY 28, 2013 MARCH 1, 2013
EXPERT CONFERENCE ON THE REVISION OF DECLARATION OF HELSINKI IMPERIAL HOTEL, TOKYO TOKYO, JAPAN FEBRUARY 28, 2013 MARCH 1, 2013 DECLARATION OF HELSINKI RESOURCE POOR SETTING & POST STUDY ARRANGEMENT BY
Regulatory Overview of Proposed LDT Framework. FDA Concerns. Background. FDA Proposed Regulatory Approach. By Ben Berg, Meaghan Bailey, RAC
Regulatory Overview of Proposed LDT Framework By Ben Berg, Meaghan Bailey, RAC On July 31, 2014, the U.S. Food and Drug Administration (FDA or the Agency) notified both the Senate Committee on Health,
Corporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
COMPASS. Meet Our Recipients: Understanding the Pathology of SMA. A Publication Dedicated to Research Updates SUMMER 2018
COMPASS A Publication Dedicated to Research Updates Cure SMA has a rich history of supporting research aimed at improving quality of life, expanding treatment options, and advancing the understanding of
Dear Chairmen Upton and Pitts, Ranking Members Pallone and Green, and Ms. DeGette:
May 29, 2015 The Honorable Fred Upton, Chairman 2125 Rayburn House Office Building The Honorable Joseph Pitts, Chairman 420 Cannon House Office Building The Honorable Frank Pallone, Ranking Member 2322A
The Importance of Participating in Clinical Trials in Alzheimer s Disease. Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute
The Importance of Participating in Clinical Trials in Alzheimer s Disease Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute First and foremost Clinical trials and studies are a
US FDA Expedited Programs and Expanded Access
US FDA Expedited Programs and Expanded Access Ke Liu, MD, PhD Chief, Oncology Branch Division of Clinical Evaluation, Pharmacology and Toxicology Office of Tissues and Advanced Therapies Center for Biologics
Disease Specific Registries vs Product Registries
1 Disease Specific Registries vs Product Registries Professor Hanns Lochmüller Newcastle University 2 What is TREAT-NMD? A network of excellence funded by the European Union (but with global collaborations)
STEM CELL SOCIETY SYMPOSIUM 2012 Stem Cell Based Therapy
STEM CELL SOCIETY SINGAPORE STEM CELL SOCIETY SYMPOSIUM 2012 Stem Cell Based Therapy 6 th to 7 th of September 2012 Auditorium, Matrix Building Level 2, 30 Biopolis Street, Singapore 138671 1 P a g e Dear
Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process
Progress Through Partnership: Actively Engaging Patient Groups in the Clinical Research Process Petra Kaufmann, MD, MSc, FAAN Director, Division of Clinical Innovation NCATS/NIH DIA MEETING, WASHINGTON